In addition to PTEN, PPARγ agonist rosiglitazone also downregulates Akt/mTOR/p70S6K signal cascade, which inhibits NSCLC cell proliferation through PPARγ-dependent and PPARγ-independent signaling [48]. Here, PTEN is linked to non-small cell lung carcinoma.